These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 14555862)

  • 1. Tolerability of rofecoxib in patients with adverse reactions to nonsteroidal anti-inflammatory drugs: a study of 216 patients and literature review.
    Perrone MR; Artesani MC; Viola M; Gaeta F; Caringi M; Quaratino D; Romano A
    Int Arch Allergy Immunol; 2003 Sep; 132(1):82-6. PubMed ID: 14555862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients.
    Senna G; Bilò MB; Antonicelli L; Schiappoli M; Crivellaro MA; Bonadonna P; Dama AR
    Eur Ann Allergy Clin Immunol; 2004 Jun; 36(6):215-8. PubMed ID: 15329003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term and long-term tolerability of rofecoxib in patients with prior reactions to nonsteroidal anti-inflammatory drugs.
    Nettis E; Colanardi MC; Ferrannini A; Tursi A
    Ann Allergy Asthma Immunol; 2005 Jan; 94(1):29-33. PubMed ID: 15702812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of selective COX-2 inhibitors in aspirin/nonsteroidal anti-inflammatory drug-intolerant patients: comparison of nimesulide, meloxicam, and rofecoxib.
    Bavbek S; Celik G; Ozer F; Mungan D; Misirligil Z
    J Asthma; 2004 Feb; 41(1):67-75. PubMed ID: 15046380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolerance of nonsteroidal anti-inflammatory drug-sensitive patients to the highly specific cyclooxygenase 2 inhibitors rofecoxib and valdecoxib.
    Sánchez-Borges M; Caballero-Fonseca F; Capriles-Hulett A
    Ann Allergy Asthma Immunol; 2005 Jan; 94(1):34-8. PubMed ID: 15702813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of rofecoxib in subjects with a history of adverse cutaneous reactions to aspirin and/or non-steroidal anti-inflammatory drugs.
    Pacor ML; Di Lorenzo G; Biasi D; Barbagallo M; Corrocher R
    Clin Exp Allergy; 2002 Mar; 32(3):397-400. PubMed ID: 11940070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolerability of meloxicam in patients with histories of adverse reactions to nonsteroidal anti-inflammatory drugs.
    Quaratino D; Romano A; Di Fonso M; Papa G; Perrone MR; D'Ambrosio FP; Venuti A
    Ann Allergy Asthma Immunol; 2000 Jun; 84(6):613-7. PubMed ID: 10875490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolerability of rofecoxib in patients with cutaneous adverse reactions to nonsteroidal anti-inflammatory drugs.
    Nettis E; Di PR; Ferrannini A; Tursi A
    Ann Allergy Asthma Immunol; 2002 Mar; 88(3):331-4. PubMed ID: 11926629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Celecoxib tolerability in patients with hypersensitivity (mainly cutaneous reactions) to nonsteroidal anti-inflammatory drugs.
    Viola M; Quaratino D; Gaeta F; Caringi M; Valluzzi R; Caruso C; Volpetti S; Romano A
    Int Arch Allergy Immunol; 2005 Jun; 137(2):145-50. PubMed ID: 15897671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma.
    Stevenson DD; Simon RA
    J Allergy Clin Immunol; 2001 Jul; 108(1):47-51. PubMed ID: 11447381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rofecoxib, as a safe alternative for acetyl salicylic acid/nonsteroidal anti-inflammatory drug-intolerant patients.
    Bavbek S; Celik G; Pasaoglu G; Misirligil Z
    J Investig Allergol Clin Immunol; 2006; 16(1):57-62. PubMed ID: 16599250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Tolerability of a selective cyclooxygenase-2-inhibitor (rofecoxib) in patients with intolerance reactions to nonsteroidal anti-inflammatory agents].
    Zollner TM; Ahlbach S; Kaufmann R; Boehncke WH
    Dtsch Med Wochenschr; 2001 Apr; 126(14):386-8. PubMed ID: 11332239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of selective cyclooxygenase-2 inhibitor rofecoxib in patients with NSAID-induced cutaneous reactions.
    Quiralte J; Sáenz de San Pedro B; Florido JJ
    Ann Allergy Asthma Immunol; 2002 Jul; 89(1):63-6. PubMed ID: 12141722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of the new selective cyclooxygenase type 2 inhibitors rofecoxib and celecoxib in patients with anaphylactoid reactions to nonsteroidal anti-inflammatory drugs.
    Quiralte J; Delgado J; Sáenz de San Pedro B; López-Pascual E; Nieto MA; Ortega N; Florido JF; Conde J
    Ann Allergy Asthma Immunol; 2004 Oct; 93(4):360-4. PubMed ID: 15521372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The selective cyclooxygenase-2 inhibitor celecoxib is a safe alternative in patients with pseudo-allergic reactions to nonsteroidal anti-inflammatory drugs].
    Ahlbach S; Usadel KH; Kaufmann R; Boehncke WH
    Med Klin (Munich); 2003 Apr; 98(5):242-4. PubMed ID: 12721666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of high-dose rofecoxib in patients with aspirin-exacerbated respiratory disease.
    Woessner KM; Simon RA; Stevenson DD
    Ann Allergy Asthma Immunol; 2004 Oct; 93(4):339-44. PubMed ID: 15521369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intolerance reactions due to the selective cyclooxygenase type II inhibitors rofecoxib and celecoxib. Results of oral provocation tests in patients with NSAID hypersensitivity.
    Kruse R; Ruzicka T; Grewe M
    Acta Derm Venereol; 2003; 83(3):183-5. PubMed ID: 12816152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of a cyclooxygenase-2 inhibitor in patients with aspirin-sensitive asthma.
    Martín-García C; Hinojosa M; Berges P; Camacho E; García-Rodriguez R; Alfaya T; Iscar A
    Chest; 2002 Jun; 121(6):1812-7. PubMed ID: 12065343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Etoricoxib tolerability in patients with hypersensitivity to nonsteroidal anti-inflammatory drugs.
    Viola M; Quaratino D; Gaeta F; Caruso C; Valluzzi R; Romano A
    Int Arch Allergy Immunol; 2007; 143(2):103-8. PubMed ID: 17228166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of ketoprofen oral challenges to detect cross-reactors among patients with a history of aspirin-induced urticaria.
    Asero R
    Ann Allergy Asthma Immunol; 2006 Aug; 97(2):187-9. PubMed ID: 16937749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.